The role of sphingosine-1-phosphate in bone remodeling and osteoporosis
Standard
The role of sphingosine-1-phosphate in bone remodeling and osteoporosis. / Grewe, Justus M.; Knapstein, Paul-Richard; Donat, Antonia; Jiang, Shan; Smit, Daniel J; Xie, Weixin; Keller, Johannes.
In: BONE RES, Vol. 10, No. 1, 34, 08.04.2022.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The role of sphingosine-1-phosphate in bone remodeling and osteoporosis
AU - Grewe, Justus M.
AU - Knapstein, Paul-Richard
AU - Donat, Antonia
AU - Jiang, Shan
AU - Smit, Daniel J
AU - Xie, Weixin
AU - Keller, Johannes
N1 - © 2022. The Author(s).
PY - 2022/4/8
Y1 - 2022/4/8
N2 - Osteoporosis is a systemic bone disease that affects more than 200 million people worldwide and is caused by the disruption of the equilibrium between osteoclastic bone resorption and osteoblastic bone formation. Sphingosine-1-phosphate (S1P) is a natural, bioactive sphingolipid that has been shown to play a major role in cardiovascular and immunological pathologies by regulating biological and cellular processes, including migration, differentiation, proliferation and survival. Recent studies also suggest a central role for S1P in bone diseases, including osteoporosis; however, the effects of S1P, particularly in bone metabolism, remain to be further elucidated. In this review, we summarize the available literature on the role of S1P in bone metabolism with a focus on osteoporosis. On the cellular level, S1P acts as an osteoclast-osteoblast coupling factor to promote osteoblast proliferation and bone formation. Moreover, the recruitment of osteoclast precursors to resorption sites is regulated by the interplay of S1P gradients and S1P receptor expression. From a clinical perspective, increasing evidence suggests that systemically elevated S1P blood levels may serve as an independent risk factor for osteoporosis-related fractures. Taken together, S1P signaling is a potential therapeutic target and may serve as a novel biomarker in patients with systemic bone disease.
AB - Osteoporosis is a systemic bone disease that affects more than 200 million people worldwide and is caused by the disruption of the equilibrium between osteoclastic bone resorption and osteoblastic bone formation. Sphingosine-1-phosphate (S1P) is a natural, bioactive sphingolipid that has been shown to play a major role in cardiovascular and immunological pathologies by regulating biological and cellular processes, including migration, differentiation, proliferation and survival. Recent studies also suggest a central role for S1P in bone diseases, including osteoporosis; however, the effects of S1P, particularly in bone metabolism, remain to be further elucidated. In this review, we summarize the available literature on the role of S1P in bone metabolism with a focus on osteoporosis. On the cellular level, S1P acts as an osteoclast-osteoblast coupling factor to promote osteoblast proliferation and bone formation. Moreover, the recruitment of osteoclast precursors to resorption sites is regulated by the interplay of S1P gradients and S1P receptor expression. From a clinical perspective, increasing evidence suggests that systemically elevated S1P blood levels may serve as an independent risk factor for osteoporosis-related fractures. Taken together, S1P signaling is a potential therapeutic target and may serve as a novel biomarker in patients with systemic bone disease.
U2 - 10.1038/s41413-022-00205-0
DO - 10.1038/s41413-022-00205-0
M3 - SCORING: Review article
C2 - 35396384
VL - 10
JO - BONE RES
JF - BONE RES
SN - 2095-4700
IS - 1
M1 - 34
ER -